Mesoblast reports operational and financial highlights for quarter ended december 31, 2022

New york, feb. 27, 2023 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights and financial results for the period ended december 31, 2022.

MESO Ratings Summary

MESO Quant Ranking